A reader-first platform. Evidence is explained; paid relationships are disclosed.
Longevity products and services often come with confident claims. Readers deserve to see the original evidence, its limits, the full cost and any commercial relationship behind a recommendation.
We are building a research publication and practitioner directory. We do not sell supplements or provide medical care. Our aim is to trace material claims to primary sources, label the strength of evidence and disclose paid relationships where they exist.
The longevity field includes useful research, open questions and treatments that need careful clinical oversight. We will explain each in language a reader can use to make a better decision.
Editorial standards
We cite the original trial, not a press release, a secondary review, or an influencer summary of it. Every factual claim carries a reference to the primary source — journal, lead authors, year of publication. If we cannot cite the primary source, the claim does not appear.
The MHRA prohibits therapeutic claims that imply a product diagnoses, treats, cures, or prevents disease unless it holds a marketing authorisation. We describe what the evidence shows in human trials — not what a compound does to "your health". This is not a technicality. It is how we keep the information honest.
No practitioner ranking or patient-review score is active. When verified profiles are published, any paid placement will be labelled and kept separate from credential checks. Editorial evidence conclusions will not be sold.
Every claim on this platform carries its evidence tier — Tier 1 (RCT/meta-analysis), Tier 2 (mechanistic/observational), or Tier 3 (emerging/case series). Claims without a tier assignment do not appear. Tier 1 and Tier 3 evidence mean fundamentally different things, and readers deserve to know which they are looking at.
Who we are
ProvenLongevity was founded by independent health researchers frustrated by the gap between what the published literature says and what the longevity industry communicates to the public. We are not clinicians offering medical advice. We are researchers committed to accurate, primary-source-referenced communication of what the evidence shows.
We are exploring affiliate commissions, clearly labelled sponsorship and verified practitioner listings. These are proposed routes, not a claim that any merchant or practitioner has joined. We will disclose each active paid relationship and keep evidence assessments independent.
We start with UK readers. We check relevant UK regulatory and professional sources for each published guide and identify other jurisdictions when they matter.
What we are not
Clarity on what this platform is not matters as much as what it is:
Evidence framework
Every compound profile and every clinical claim on ProvenLongevity is tagged with its evidence tier. The tier system is not a value judgement — Tier 3 evidence can be important and worthy of attention. It is a transparency mechanism: readers can see immediately what kind of evidence a claim rests on.
Direct experimental evidence in humans. Randomised controlled trials with control groups, pre-registered outcomes, and adequate statistical power — or systematic reviews pooling multiple RCTs. The highest standard of clinical evidence we apply. Compounds at Tier 1 have demonstrated effects under controlled conditions in human participants.
Strong mechanistic rationale confirmed in human biology, supported by observational studies, cohort studies, or small RCTs. Clinical outcomes in large controlled human trials have not yet been established. This tier warrants serious attention — the mechanism is real, the signals are there — but confidence in clinical effect is lower than Tier 1.
Early-stage human evidence: case reports, pilot studies, small open-label trials without control groups, or preclinical data with early human signals. Mechanistically plausible but insufficiently studied in controlled human settings to draw clinical conclusions. Presented for completeness and transparency, not as a recommendation.
For editorial corrections, directory questions or press enquiries, write to isacreative.contact@gmail.com.